In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management
Session

Event : ESC Congress 2017

Topic : Chronic Heart Failure - Other

  • Session type : Satellite Symposium
  • Date : 27 August 2017
  • Time : 12:45 - 13:45
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

5 presentations in this session

Introduction - Enabling and renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.

Event : ESC Congress 2017

  • Session : Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management
  • Speaker : M Boehm (Homburg,DE)
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Renin-angiotensin-aldosterone system inhibitor therapy benefit and challenges in cardio-renal patients.

Event : ESC Congress 2017

  • Session : Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management
  • Speaker : M Weir (Baltimore,US)
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Changing the treatment paradigm of hyperkalaemia management to enable and optimise renin-angiotensin-aldosterone system inhibitor therapy.

Event : ESC Congress 2017

  • Session : Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management
  • Speaker : S Anker (Berlin,DE)
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Panel discussion - Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.

Event : ESC Congress 2017

  • Session : Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management
  • Speaker : M Boehm (Homburg,DE)
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Summary and conclusion - Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management.

Event : ESC Congress 2017

  • Session : Enabling and optimising renin-angiotensin-aldosterone system inhibitor therapy in cardio-renal patients through hyperkalaemia management
  • Speaker : M Boehm (Homburg,DE)
  • Sponsored by Vifor Pharma/Vifor Fresenius Medical Care Renal Pharma

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are